Bioo Therapeutics’ primary objective is to develop therapeutic agents and drug delivery vehicles to combat cancer. We are meeting this objective by developing innovative on antibody-based and small molecule drugs and cancer targeting drug delivery vehicles.
Therapeutic Milestones
Obtained a 50,000 member chemical compound library for discovering drug candidates for cancer therapy - May 2009
Initiated pre-clinical testing of a lead cancer targeting drug BIOO1 - June 2009
Identified six more cancer drug candidates and expect to initiate preclinical analysis by 2010
Delivery Milestones
Obtained $500,000 in funds from federal agencies to initiate directed delivery program - August 2009
Signed a collaboration agreement with Texas Tech to develop Bioo’s targeted transport technology - September 2009
Initiated animal testing of T3™ Targeted Transport Technology - October 2009
Launched the T3™ Conjugation Kit which offer effective delivery of siRNA or microRNA (miRNA) into any targeted cell or tissue type - December 2009
Bioo Therapeutics, 3913 Todd Lane Suite 312 Austin, TX 78744, USA Phone: 888-208-2246 Copyright 2009
